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Both epidemiological investigations and animal studies have linked arsenic 
contaminated water to cancers. Besides genotoxicity, arsenic exposure-related 
pathogenesis of disease is widely considered through epigenetic mechanisms; 
however, the underlying mechanism remains to be determined. Herein we explore 
the initial epigenetic changes via acute low-dose arsenite exposures of mouse 
embryonic fibroblast (MEF) cells and histone H3K79 methyltransferase DOT1L 
knockout MEF (Dot1L-/-) cells. 
First, we decided the exposure concentration and time of sodium arsenite 
according to the expression of Nrf2. We started our exposure experiments with two 
time points (6 and 24 h) and four concentrations (0, 2, 5, and 10 μM). After 6 h 
treatment, the amount of Nrf2 showed dose-effect relationships with the 
concentrations of sodium arsenite in both cell lines and there were significant 
difference between 2 μM and 5 μM groups. The amount of Nrf2 after 24 h exposure 
also showed dose-effect relationships with the concentrations of sodium arsenite. 
However, compared with 6 h groups, 24 h groups showed different pattern of Nrf2 
 iii 
expression between two cell lines, which might be caused by Dot1L lacking. 
Collectively, we consider 5 μM and 24 h appropriate for our further mechanistic 
exploration. 
Second, RNA-seq data demonstrated that, in both cell lines, acute low-dose 
arsenite exposure inhibited the transcription of histone acetyltransferase gene EP300. 
These results were validated by qRT-PCR. Western blot results also showed the 
down-expression of p300. Then H3K27ac and H3K4me1 antibody were used for 
ChIP-seq to observe histone modification changes caused by p300 down-regulation. 
Consequently, p300-specific main target histone H3K27ac, decreased dramatically 
as validated by both Western blot and ChIP-seq analyses. Concomitantly, H3K4me1 
as another well-known marker for enhancers also showed significant decreases, 
suggesting an underappreciated crosstalk between H3K4me1 and H3K27ac involved 
in arsenite exposure.  
Third, arsenite exposure-reduced H3K27ac and H3K4me1 inhibit the expression 
of genes, including EP300 itself and Klf4. Both of them are tumor suppressor genes. 
These results were validated by ChIP-seq and qRT-PCR. 
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Collectively, our investigations identify p300 as an internal bridging factor within 
cells to sense external environmental arsenite exposure to alter chromatin, thereby 
changing gene transcription for disease pathogenesis. 
Primary reader: Zhibin Wang 
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1. Introduction and Background 
This chapter included three parts. The first part introduced several diseases 
related to arsenic exposure, especially arsenic in drinking water. The second part 
reviewed the relationship between arsenic exposure and Nrf2 expression. The third 
part focused on epigenetic changes after arsenic exposure, including DNA 
methylation and histone modifications.  
1.1. Arsenic related diseases 
Arsenic, as an ubiquitous element, ranks the 20th most abundant element in the 
earth’s crust (Mandal and Suzuki 2002). Human exposure to environmental arsenic 
occurs primarily via ingestion of inorganic arsenic contaminated water. It is estimated 
that over 200 million individuals worldwide are exposed to drinking water containing 
arsenic above 10 µg/L, the safety standard set by WHO (Argos et al. 2014). 
Epidemiological researches have validated the positive relationship between arsenic 
in drinking water and several diseases, including cancers, pulmonary, cardiovascular, 
liver, and neurological system diseases.  
1.1.1. Tumors related to arsenic exposure 
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Through numerous epidemiological investigations (shown in Table 1:1), 
accumulating evidences demonstrate the positive relationship between inorganic 
arsenic and carcinomas, including both skin and internal cancers. Investigations 
focused on arsenic and skin cancer began since the 1960s. An epidemiological result 
about the relationship between skin cancer and arsenic in well water was found in 
Taiwan (Yeh et al. 1968). The overall prevalence of skin cancer was 10.6/1000 and 
more than 10 % of the population over 59 years old suffered skin cancer. This 
research also reported a dose-effect relationship between concentrations of arsenic 
for both sexes in three different age groups. Furthermore, arsenic concentrations 
showed a significant dose-response relationship with skin tumor of both sexes in 
Taiwan (Wu et al. 1989). In Wisconsin, USA, residents who were over 35 years old 
and consumed arsenic-contaminated water for more than a decade suffered a higher 
prevalence of skin cancer than control group (Knobeloch et al. 2006).  
Significant dose-response relationships between arsenic concentrations and 
internal tumors were found in Taiwan, including bladder, kidney, and lung cancer in 
both sexes, and tumors of prostate and liver in males (Wu et al. 1989). Besides, a 
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dose-response relationship between arsenic exposure from drinking artesian well 
water and the incidence of lung or bladder cancer was observed in Taiwan (Chiou et 
al. 1995). Furthermore, there was a monotonic trend between lung cancer risk and 
arsenic level from drinking water in Taiwan (Chen et al. 2004). Compared with the 
lowest group (arsenic level less than 10 µg/L), the relative risk of lung cancer in the 
highest group (arsenic level more than 700 µg/L) was 3.29 (95% CI, 1.60-6.78). 
In other areas, a case-control study in Chile showed that lung cancer odds ratios 
increased from 1.6 (95% CI, 0.5–5.3) in the group with arsenic concentration less 
than 10 µg/L to 8.9 (95% CI, 4.0 –19.6) in the group with 200-400 µg/L (Smith et al. 
1992). Another case-control study in Argentina showed that there was a positive 
association between using well water for more than 50 years and bladder cancer risk 
among ever smokers (Bates et al. 2004). These results suggested that 
arsenic-induced bladder cancer should need a long period of exposure and the 
involvement of other carcinogens, which was validated by another fifty-year study 
(Marshall et al. 2007). This validation showed that the mortality resulting from lung 
and bladder cancers kept high until 25 years after the significant decreases of arsenic 
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exposure. An association between arsenic in low exposure level and bladder cancer 
was observed in Finland (Kurttio et al. 1999). Compared with lowest group (arsenic 
level less than 0.1 µg/L), the relative risk of bladder cancer in highest group (arsenic 
level more than 0.5 µg/L) was 2.44 (95% CI, 1.11-5.37). Meta-analyses showed that, 
with the increasing of arsenic in the drinking water, the risk of bladder cancer elevated 
accordingly (Saint-Jacques et al. 2014). A US-based prospective cohort also reported 
an association between low to moderate exposure to inorganic arsenic and increased 
mortality from cancers of the lung, prostate, and pancreas (Garcia-Esquinas et al. 
2013). 
Besides, early exposure to arsenic increases the incidences of tumors later. For 
young adults aged 30 to 39 years old in Chile, early-life exposure to arsenic in 
drinking water resulted in an increased kidney cancer mortality rate ratio of 7.1 (95% 
CI, 3.1-14) (Yuan et al. 2010). In another cohort of 30-49 years age old with probable 
arsenic exposure in utero and early childhood, the corresponding Standardized 
Mortality Ratio (SMR) for lung cancer was 6.1 (95% CI, 3.5-9.9) (Smith et al. 2006b). 
Furthermore, several cell lines and different concentrations of arsenic were used in 
 5 
arsenic-induced malignant transformation, which were shown in Table 1-1. 
Table1-1 Cell models used in arsenic-induced malignant transformation 
Models Methods Results Reference 
TRL 1215,a cell line 
derived from the 
liver of 10-day old 






changes every 3 
days 
Cells were passaged 
once a week 
8 weeks of exposure: 5% 
of cell exhibited 
morphological changes 
from epithelioid to 
fibroblast-like 
18 weeks of exposure: 
70% of cell exhibited 
morphological changes, 
and could develop tumor 








changes every 3 
days 
Cells were passaged 
once a week 
Increased expressions of 
AFP, WT-1, c-jun, c-myc, 
H-ras, c-met 









A significant increase in 
matrix metalloproteinase-9 
expression, a common 











saturation density, plating 
efficiency, and 
anchorage-independent 
growth and invasion 
capability 










breast epithelial (CABE) 
showed markers of cancer 
cell phenotype. 










Increased Hdm2 and p53 
in the cytoplasm, 
compromise response of 








Increased expression of 
matrix metalloproteinase-9 
(MMP-9), keratin-1, 
keratin-10, and Nrf2 





Acute: 100 μM for 4 
Increased expression of 





originated from the 
urothelial cells of a 
12-year-old female 
donor 
h followed by a 48-hr 
recovery period 
Chronic: 1, 4, and 8 





30 days of exposure 
and 30 following 
days of treatment 
every 3 days 
Formed colonies in soft 




1.1.2. Pulmonary diseases related to arsenic exposure 
Arsenic exposure has been related to several non-malignant lung diseases. In 
Bangladesh, the prevalence of chronic bronchitis showed a dose-effect relationship 
with arsenic in drinking water (Milton and Rahman 2002). Data from another 
case-control study demonstrated that the prevalence of chronic cough and bronchitis 
in arsenic exposed group was three times higher compared with control group (Milton 
et al. 2001). In Chile, a case-control study showed that there was a positive 
association between mortality caused by bronchiectasis and exposure to arsenic in 
utero and in early age (Smith et al. 2006a). Another investigation showed that 
early-life exposure of arsenic was associated with several lung dysfunctions, 
including decreased forced expiratory volume in 1s, decreased forced vital capacity 
and increased breathlessness (Steinmaus et al. 2016). 
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1.1.3. Cardiovascular diseases related to arsenic exposure 
Arsenic is associated with several cardiovascular diseases since arsenic induces 
endothelial dysfunction through different mechanisms, including inflammation, blood 
coagulating system and nitric oxide imbalance (Simeonova and Luster 2004). The 
association between arsenic in drinking water and mortality due to heart diseases 
was reported in Bangladesh (Chen et al. 2011a). Besides, after the cessation of 
drinking water with high arsenic, mortality attributed to ischemic heart disease 
declined in Taiwan (Chang et al. 2004). In a cohort study from Taiwan, residents with 
chronic arsenic exposure showed a 1.5 fold higher prevalence of hypertension 
compared with unexposed individuals (Chen et al. 1995). Another research in Taiwan 
showed the dose-effect relationship between arsenic ingestion and peripheral 
vascular disease (Tseng et al. 1996). Standard mortality ratio of hypertensive heart 
disease in exposed group was 2.20 in Millard County, Utah (Lewis et al. 1999). In a 
cross-sectional study, chronic arsenic exposure was associated with QT prolongation, 
a contributor of arrhythmia and sudden cardiac death (Mordukhovich et al. 2009).  
1.1.4. Liver diseases related to arsenic exposure 
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As the organ that responsible for the biotransformation of inorganic arsenic, liver 
is a main organ that suffers arsenic toxicity. Chronic arsenic exposure led to an 
increasing bilirubin, alanine transaminase, aspartate transaminase, and alkaline 
phosphatase in the serum, indicating liver injury in West Bengal, India (Abdul et al. 
2015). Among individuals inhaling arsenic due to burning arsenic-containing coal, 
hepatomegaly prevalence was 20% in Guizhou, China (Liu et al. 2002).  
1.1.5. Neurological diseases related to arsenic exposure 
Arsenic causes diverse symptoms on central nervous system in both human and 
animal models. A case-control study reported that children with chronic arsenic 
exposure showed limited long-term memory and linguistic abstraction in Mexico 
(Calderon et al. 2001). And adolescents with arsenic exposure from drinking water 
also demonstrated affected pattern memory and switched attention in Taiwan (Tsai et 
al. 2003). A five-year follow-up in smelter workers suggested that peripheral nerves 
symptoms were caused by long-term exposure of arsenic rather than short-term 
(Lagerkvist and Zetterlund 1994). In a patient with homeopathic treatment (containing 
arsenic), a toxic polyneuropathy with quadriparesis was reported (Chakraborti et al. 
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2003). A biopsy report found that arsenic disturbed degeneration and regeneration of 
nerve fibers (Goebel et al. 1990). Besides, neuropathic symptoms continued more 
than one year after the arsenic exposure suspended (Vantroyen et al. 2004). 
1.1.6. Renal diseases related to arsenic exposure 
Arsenic is eliminated through renal system, which is another main target of 
arsenic toxicity. Standard mortality ratio of nephritis and nephrosis in the exposed 
group was 1.72 in Millard County, Utah (Lewis et al. 1999). Besides, arsenic levels 
showed a dose-effect relationship with the chronic kidney disease in Taiwan (Hsueh 
et al. 2009). A cohort study suggested a positive relationship between arsenic in 
drinking water and proteinuria, which decreased after the reduction of arsenic 
absorption (Chen et al. 2011b). In another cohort study, the concentration of arsenic 
in urine showed an association with the prevalence of albuminuria (Zheng et al. 
2013). 
1.2. Nrf2 and arsenic exposure 
Nrf2 is one of basic region leucine zipper (bZip) transcription factors and plays a 
significant role in eliminating oxidant stress (Ma 2013). Nrf2 is used to determine the 
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minimal concentration that causes significant toxic reactions. Nrf2 was reported as a 
transcription factor, which binds to ARE elements in the promoter regions (Huang et 
al. 2000), and Nrf2-Keap1 pathway plays a significant role in metabolic 
biotransformation of xenobiotics (Motohashi and Yamamoto 2004). Nrf2 can promote 
the expression of cytoprotective genes, including Aldo-keto reductases (Lou et al. 
2006), Glutamate cysteine ligase (Chan and Kwong 2000), Glutathione 
S-transferases (Chanas et al. 2002), Glutathione synthetase (Lee et al. 2005), and 
Metallothionein (Yeh and Yen 2005).  
Besides, several researches reported its relationship with detoxication of arsenic. 
Nrf2 gene expression can be activated by inorganic arsenic exposure in osteoblasts 
(Aono et al. 2003). With exposure of 800 uM arsenate, expression of Nrf2 increased 
significantly with 4 h and peaked at 16 h. While treated with 100 uM arsenite, Nrf2 
expression reached maximum at 12 h. These increased expressions promoted 
transcription of target genes, including HO-1, Prx I, and A170. The increased 
transcriptional and protein level of Nrf2 were also reported in HaCaT cells (Pi et al. 
2003). In MDA-MB-231 cell line, inorganic arsenite enhanced Nrf2 protein level by 
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blocking its ubiquitination and degradation (Wang et al. 2008). 
Furthermore, the expression of Nrf2 can be regulated by epigenetic mechanisms. 
For example, promoter hypermethylation decreased Nrf2 expression in TRAMP mice 
(Yu et al. 2010). In TRAMP C1 cells, hypomethylation of CpG sites in Nrf2 promoter 
induced by both curcumin and sulforaphane reversed the low expression of Nrf2 
(Khor et al. 2011). Furthermore, TPA induced promoter hypermethylation of Nrf2 in 
mouse skin epidermal JB6 (Su et al. 2014). Besides DNA methylation, alterations of 
histone modification are linked to Nrf2 expression. EZH2, a histone H3K27 
trimethyltransferase, increased H3K27me3 in the promoter of Nrf2 and inhibited Nrf2 
expression (Li et al. 2014). In chronic obstructive pulmonary disease, Nrf2 expression 
level decreased due to down-regulation of histone deacetylase 2 (Mercado et al. 
2011).  
In a mouse model, after arsenite exposure intragastrically, Nrf2 transcription 
elevated dose-dependently in the cerebral cortex and hippocampus (Zhang et al. 
2016). In another mouse model with 6 weeks of arsenite, Nrf2 ameliorated liver and 
bladder injury (Jiang et al. 2009). Acute arsenite exposure in mouse activated Nrf2 in 
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spleen, thymus, and peripheral blood mononuclear cells (Duan et al. 2015). 
1.3. Epigenetic changes after arsenic exposure 
Epigenetics is the study of heritable and reversible changes in gene expression 
that occur without a change in the DNA sequence, including histone modification, 
DNA methylation, and microRNA (Collotta et al. 2013). In the early stage, researches 
of epigenetics (mainly DNA methylation) focused on its role in embryonic 
development, cell differentiation, X-chromosome inactivation, and terminal 
differentiation (Fuso 2013). Since then, associations between epigenetics and 
different cancers were observed. With the development of technology in 
high-throughput sequencing, we can detect and analyze epigenetics in a deeper and 
more accurate way. At present, it is still difficult to determine specific genetic and 
environmental factors in complex diseases, such as cancers, diabetes, and 
neurodegenerative diseases; however, accumulating evidences suggest that 
epigenetics may be the linkage between genes and environment, providing possible 
clues to understand the etiology of these complex diseases.  
1.3.1. DNA methylation 
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DNA methylation is the earliest characterized chromatin modifications. The 
methylation of CpG dinucleotides at the 5¢ position on the pyrimidine ring, to form 
5-methylcytosine (5-mC), can inhibit transcription and bring about gene silencing by 
initiating chromatin compaction, blocking transcription factors binding and attracting 
methyl-binding proteins, particularly at promoters (Lunnon and Mill 2013). So 
hypermethylation results in gene down-regulation, while de-methylation causes gene 
up-regulation.S-adenosyl-methionine (SAM) is essential for methylation of inorganic 
arsenic to detoxication, and it is also the methyl-donor required by DNA 
methyltransferases. It is reasonable to speculate that arsenic exposure leads to 
hypo-methylation of DNA and facilitates oncogenes expression, which was validated 
in TRL 1215 cell line (Zhao et al. 1997). Other DNA methylation changes caused by 
different concentrations of arsenic were shown in Table 1-2 
Inorganic As exposure in drinking water increased lung tumor incidence and 
multiplicity in A/J mice, which involved hypomethylation of tumor suppressor genes, 
including p16INK4a and RASSF1A (Cui et al. 2006a). In a cohort of human bladder 
cancer of USA, arsenic exposure was associated with RASSF1A and PRSS3 but not 
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p16INK4A promoter methylation (Marsit et al. 2006). Among skin cancer subjects 
who were also exposed to arsenic, blood cell DNA showed methylation alterations in 
TP53 and TP16 genes (Chanda et al. 2006).  
In A549 cells, sodium arsenite (0.08-2 μM) and sodium arsenate (30–300 μM) 
showed significant dose-responsive relationships with percentage of 
hypermethylation in the promoter of TP53 (Mass and Wang 1997). In another arsenic 
treated A549 cell, arsenic exposure led to hypermethylation of six fragments and 
hypomethylation of two fragments in 5¢ control region of the tumor suppressor gene. 
Besides, arsenic inhibited the expression of the DNA methyltransferase genes, 
including DNMT1 and DNMT3a (Reichard et al. 2007).These results suggested that 
hyper- and hypo- methylation coexisted after arsenic exposure and altered 
methylation might be a potential mechanism of arsenic-induced carcinogenesis 
(Zhong and Mass 2001).  
Table1-2 DNA methylation changes caused by arsenic exposure 
Objects Treatment or exposure Results Reference 
Human lung 
adenocarcinoma 
A549 cell line 
Sodium arsenite 
(0.08-2 mM) or 
sodium arsenate 
(30-300 mM) for 2 
weeks 
Medium was changed 
twice weekly. 
Hypermethylation in 























Caco-2 cell line 
0, 1 or 2 μM sodium 
arsenite for 7 d 
Medium was changed 
every 2 d 
Hypermethylation in 
TP53 
(Davis et al. 
2000) 
Human kidney 
UOK cell line 
0.08–2 μM sodium 
arsenite or 30–300 μM 
sodium arsenate 
heptahydrate 
for 4 weeks 










As sodium arsenite 
1 μM 
52 weeks 
Aberrant DNA methylation 
occurred non-randomly, 
progressed gradually at 








12 weeks or 24 
weeks 
12 weeks: an increased 
growth rate and 
anchorage-independent 
growth. DNA methylation 
remains relatively 
unchanged. 





epithelial cell line, 
RWPE-1 
5 μM sodium arsenite 




aa et al. 2005) 





Arsenic in the 
environment 
Hypermethylation in 
promoter of TP53 
and TP16 
(Chanda et al. 
2006) 
Human liver cancer 
cell line HepG2 
2 to 10 μM arsenic 






(Cui et al. 
2006b) 













cell line SV-HUC-1 
2, 4, and 10 μM 
























(Reichard et al. 
2007) 






















(Coppin et al. 
2008) 














lines Molt4, U937, 
MUTZ-1, U266, 
and CA46 





(Fu et al. 2010) 











(Majumdar et al. 
2010) 
Human urothelial 
cell line SV-HUC-1 
1, 4, and 10 μM 




(Huang et al. 
2011) 









(Smeester et al. 
2011) 
















16 patients with 
pre-diabetes 









(Bailey et al. 
2013) 
Human liver cancer 
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1.3.2. Histone modification 
Changes of histone modifications after arsenic exposure are shown in Table 1-3. 
In a case-control study from Bangladesh, arsenic in water showed a positive 
relationship with H3K4me3 and H3K27me3 in females and a negative one in males. 
However, arsenic in water showed a negative relationship with H3K27ac and 
H3K18ac among females and a positive one among males (Chervona et al. 2012c). 
In another study from Bangladesh, arsenic in drinking water induced global increased 
H3K9me2 and decreased H3K9ac (Arita et al. 2012). In human lymphocytes, arsenite 
exposure was related to increased H3K9me3 and H3K9ac (Pournara et al. 2016).  
In A549，arsenite exposure decreased H3K27me3 and increased H3K9me2 and 
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H3K4me3 (Zhou et al. 2008). Besides, arsenite also stimulated the expression of 
histone methyltransferase G9a at mRNA and protein levels, which was responsible 
for H3K9 methylation (Suzuki and Nohara 2013; Zhou et al. 2008). In HepG2 
hepatocarcinoma cells, sodium arsenite induced global histone acetylation because it 
could inhibit the function of HDACs (Ramirez et al. 2008).  
In Drosophila, arsenic exposure induced de-acetylation and de-methylation of 
histones (Arrigo 1983). In yeast, arsenite exposure decreased H4K16ac in a time and 
dose dependent manner (Jo et al. 2009b). Mouse offspring exposed to arsenic during 
embryonic stage showed increased H3K9ac (Cronican et al. 2013b).  
Table1-3 Histone modification changes caused by arsenic exposure 
Objects Treatment or exposure Results Reference 
Human diploid 
fibroblast WI-38 
400 M sodium 





in c-fos and c-jun 
chromatin 
(Li et al. 2003) 
Hybrid of HeLa and 
human fibroblasts 
CGL-2 
1–10 μM sodium 




(Yih et al. 2005) 
HepG2 
7.5, 10, 15, and 50 μM 
sodium arsenite for 2, 
4, 12, or 24h 
Increased H3K9ac (Ramirez et al. 2008) 
HaCaT 
10 μM sodium 





(Huang et al. 
2013) 
UROtsa 1, 3, 10 μM sodium arsenite 
Decreased 
H4K16ac (Jo et al. 2009a) 










1 μM for 24 h or 




and kept 7 days 
after elimination of 1 
uM arsenite. Both 
H3K4me3 and 
H3K9me2 increased 
globally after 24 h 
exposure to arsenite 
in 1 uM. 
(Zhou et al. 
2009) 
A549 1 μM sodium arsenite for 24 h Increased H3K4me3 
(Zhou et al. 
2009) 
1.4. Concentrations of arsenite chosen in previous investigations 
In epidemiological investigations, the concentrations of arsenite in the highest 
groups were detected at 0.09 µg/ml (Marshall et al. 2007), 0.2 µg/ml (Bates et al. 
2004), 0.4 µg/ml (Smith et al. 1992), 0.6 µg/ml (Wu et al. 1989) or 0.7 µg/ml (Chiou et 
al. 1995). Detailed data are shown in Table 1-5. In cell culture experiments of arsenic 
induced malignant transformation or epigenetic changes, 0.08 µg/ml (Zhong and 
Mass 2001), 0.5 µg/ml (Zhao et al. 1997), 1 µg/ml (Jensen et al. 2009a), 2 µg/ml 
(Mass and Wang 1997), and 5 µg/ml (Achanzar et al. 2002) arsenite were used. 
Considering all concentrations mentioned above, we choose 0, 0.26, 0.65, and 1.30 
µg/ml (namely 0,2,5, and 10 uM) arsenite for the pilot experiment.  
As for cell lines, Mouse embryo fibroblast (MEF) (Chen et al. 2003), TRL 1215 
(rat live cell) (Zhao et al. 1997), RWPE-1 (human prostate epithelial cell) (Achanzar et 
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al. 2002), H-TERT (human small airway epithelial cells) (Wen et al. 2008), HaCaT 
(human keratinocytes) (Huang et al. 2008) and MCF-10A (breast epithelial cell) (Xu et 
al. 2014) were reported as the cell model of arsenic exposure.  
We chose MEF cells and Dot1L-/- cell for several reasons. At first, embryo 
fibroblast work as reservoirs of multi-potent progenitors (Singhal et al. 2016), so it 
owns the ability to differentiate into these cell lines mentioned above and its 
responses to arsenic exposure maybe include pathways in other cell lines. Besides, 
many studies have been conducted on pathways of MEF after the exposure of 
arsenic, including c-jun N-terminal kinase (Davison et al. 2004), nuclear factor κB 
kinase (Chen et al. 2003), hedgehog (Kim et al. 2013) and p53 (Yan et al. 2011). 
Meanwhile, we have Dot1L-/- cells with depleted histone mark H3K79 dimethylation 
(H3K79me2) and H3K79 methylation may be associated with arsenic exposure, 
though still very preliminary according to an epidemiology study (Howe et al. 2017). 
Therefore, treatments to both MEF and Dot1L-/- help to determine the crosstalk 
between arsenic exposure and histone H3K79me2 marks in cells. Furthermore, 
treatments of two independent cell lines would serve as replicates.  
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2. Materials and Methods 
part shows the procedures and methods during experiment (Figure2-1). In 
general, cells are treated in four different arsenite concentrations (0, 2, 5, and 10 uM) 
for 6 or 24 h. The expression levels of Nrf2 are examined through Western blot to 
determine the minimal concentration of arsenite causing significant toxic reaction. 
This determined concentration and period are used in the treatment. Cells are 
collected for mRNA-seq and ChIP-seq to examine the involvement of disease related 
genes.   
 
Figure2-1 Flow chat of the whole experiment 
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2.1. Cell culture 
MEF is diploid and nontumorigenic. Cells are treated with different concentrations 
of sodium arsenite (0, 2, 5, and 10 mM) for 6 or 24 h in the pre-experiment. Culture 
medium is high glucose Dulbecco's Modified Eagle Medium with 10% fetal bovine 
serum. To get enough cells, a large number of cells are treated with determined 
concentration of arsenite and time. 
Deionized distilled water is used in the control group. 0.013 g sodium arsenite is 
dissolved in 100 ml deionized distilled water and solution is filtered by 0.22 µm filter. 
The original concentration of sodium arsenite is 1 mM. Different volumes of solution 
are added to 20 ml medium to get target concentrations (shown in Table 2-1). Cells 
are incubated at 37 °C in 5% CO2.  
Table2-1 Different volumes of arsenite solution used for target concentrations 
Group Arsenite Concentrations Medium Volume Arsenite solution Volume 
1 0 uM (0 µg/ml) 20 ml 0 μl (20 μl water) 
2 2 uM (0.26 µg/ml) 20 ml 20 μl 
3 5 uM (0.65 µg/ml) 20 ml 100 μl 
4 10 uM (1.30 µg/ml) 20 ml 200 μl 
2.2. Western blot  
(According to instructions from Abcam) 
1. Sample lysis 
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1) Place the cell culture dish on ice and wash the cells with ice-cold PBS. 
2) Aspirate the PBS, then add ice-cold lysis buffer (1 ml per 107 cells for 100 
mm dish). 
3) Scrape adherent cells off the dish using a cold plastic cell scraper, and then 
gently transfer the cell suspension into a pre-cooled micro-centrifuge tube.  
4) Maintain constant agitation for 30 min at 4 °C. 
5) Centrifuge in a micro-centrifuge at 4 °C for 20 min at 12,000 rpm 
6) Gently remove the tubes from the centrifuge and place on ice, aspirate the 
supernatant and place in a fresh tube kept on ice, and discard the pellet. 
2. Sample preparation 
1) Remove a small volume of lysate to perform a protein quantification assay. 
Determine the protein concentration for each cell lysate. 
2) Determine how much protein to load and add an equal volume 2X Laemmli 
sample buffer. 
3) To reduce and denature your samples, boil each cell lysate in sample buffer 
at 100 °C for 5 min. Lysates can be aliquot and stored at -20 °C for future 
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use. 
3. Loading and running the gel 
1) Load equal amounts of protein into the wells of the SDS-PAGE gel, along 
with molecular weight marker. Load 20-30 μg of total protein from cell lysate 
or tissue homogenate, or 10-100 ng of purified protein. 
2) Run the gel for 2 h at 100 V. 
4. Transferring the protein from the gel to the membrane 
The membrane can be either nitrocellulose or PVDF. Activate PVDF with 
methanol for 1 min and rinse with transfer buffer before preparing the stack. The 
time and voltage of transfer may require some optimization. Transfer of proteins 
to the membrane can be checked using Ponceau S staining before the blocking 
step. 
5. Antibody staining 
1) Block the membrane for 1 h at room temperature or overnight at 4 °C using 
blocking buffer. 
2) Incubate the membrane with appropriate dilutions of primary antibody in 
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blocking buffer at 4 °C. 
3) Wash the membrane in three washes of TBST, 5 min each. 
4) Incubate the membrane with the recommended dilution of conjugated 
secondary antibody in blocking buffer at room temperature for 1 h. 
5) Wash the membrane in three washes of TBST, 5 min each. 
6) Remove excess reagent and cover the membrane in transparent plastic 
wrap. 
7) Acquire image using darkroom development techniques for 
chemiluminescence, or normal image scanning methods for colorimetric 
detection. 
2.3. RNA extraction 
(According to instructions from Invitrogen) (Chomczynski and Mackey 1995) 
1. Dissolve 106 cells in 1 ml TRIZOL. Put tubes on ice. 
2. Add 0.2 ml of chloroform per 1 ml of TRIZOL Reagent. Cap sample tubes 
securely. 
3. Vortex samples vigorously for 15 s and incubate them at room temperature for 
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2-3 min.  
4. Centrifuge the samples at 12,000x g for 15 min at 4 °C.  
5. Following centrifugation, the mixture separates into lower red, phenolchloroform 
phase, an interphase, and a colorless upper aqueous phase. RNA remains 
exclusively in the aqueous phase. Transfer upper aqueous phase carefully 
without disturbing the interphase into fresh tube.  
6. Precipitate the RNA from the aqueous phase by mixing with isopropyl alcohol. 
Use 0.5 ml of isopropyl alcohol (IPA) per 1 ml of TRIZOL Reagent used for the 
initial homogenization. 
7. Incubate samples at room temperature for 10 min and centrifuge at 12,000x g for 
10 min at 4 °C. The RNA precipitate, often invisible before centrifugation, forms a 
gel-like pellet on the side and bottom of the tube. 
8. Remove the supernatant completely. Wash the RNA pellet once with 75% 
ethanol, adding at least 1 ml of 75% ethanol per 1 ml of TRIZOL Reagent used 
for the initial homogenization.  
9. Mix the samples by vortex and centrifuge at 7,500x g for 5 min at 4 °C. Repeat 
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above washing procedure once. Remove all leftover ethanol. 
10. Air-dry or vacuum dry RNA pellet for 5-10 min. 
11. Dilute RNA with 40 μl of DEPC-treated water 
2.4. mRNA sequencing sample preparation 
(According to instructions from Illumina) 
1. Purify the beads 
1) Place the tube containing the beads on the magnetic stand for at least 1-2 
min to separate the beads and the buffer. 
2) Exchange the buffer using a pipette while the tube is on the magnetic stand. 
3) Re-suspend the beads thoroughly by vortex with 0.5-1 s pulses. 
4) Centrifuge the samples in a bench top micro-centrifuge for 1-2 s to remove 
any beads or liquid from the walls of the tube. 
5) Repeat steps 1 through 4 as required. 
2. Purify the mRNA 
1) Preheat one heat block to 65 °C and the other heat block to 80 °C. 
2) Dilute the total RNA with nuclease-free water to 50 μl in a 1.5 ml RNase-free 
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non-sticky tube. 
3) Heat the sample in a preheated heat block at 65 °C for 5 min to disrupt the 
secondary structures and then place the tube on ice. 
4) Aliquot 15 μl of Sera-Mag oligo (dT) beads into a 1.5 ml RNase-free 
non-sticky tube. 
5) Wash the beads two times with 100 μl of Bead Binding Buffer and remove 
the supernatant. 
6) Re-suspend the beads in 50 μl of Bead Binding Buffer and add 50 μl of total 
RNA sample from step 3. 
7) Rotate the tube from step 6 at room temperature for 5 min and remove the 
supernatant. 
8) While the tube is incubating, aliquot 50 μl of Binding Buffer to a fresh 1.5 ml 
RNase-free non-sticky tube. 
9) After the 5 min incubation, wash the beads from step 7 twice with 200 μl of 
Washing Buffer and remove the supernatant. 
10) Add 50 μl of 10 mM Tris-HCl to the beads and then heat in the preheated 
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heat block at 80 °C for 2 min to elute the mRNA from the beads. 
11) Immediately put the tube on the magnet stand, transfer the supernatant 
(mRNA) to the tube from step 8. Do not discard the used beads. 
12) Place the samples aside and wash the beads twice with 200 μl of Washing 
Buffer. 
13) Heat the samples in the preheated heat block at 65 °C for 5 min to disrupt the 
secondary structures and then place the samples on ice. 
14) Add the iced 100 μl of the mRNA sample from step 13 to the washed beads 
and rotate it at room temperature for 5 min, then remove the supernatant. 
15) Wash the beads twice with 200 μl of Washing Buffer and remove the 
supernatant. 
16) Add 17 μl of 10 mM Tris-HCl to the beads and heat in the preheated heat 
block at 80 °C for 2 min to elute the mRNA from the beads. 
17) Immediately put the tube on the magnet stand and then transfer the 
supernatant (mRNA) to a fresh 200 μl thin-wall PCR tube. The resulting 
amount of mRNA should be approximately 16 μl. 
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3. Fragment the mRNA 
1) Preheat a PCR thermal cycler to 94 °C. 
2) Prepare the following reaction mix in a 200 μl thin wall PCR tube: 
l 5X Fragmentation Buffer (4 μl) 
l mRNA (16 μl) 
l The total volume should be 20 μl. 
3) Incubate the tube in a preheated PCR thermal cycler at 94 °C for exactly 5 
min. 
4) Add 2 μl of Fragmentation Stop Solution. 
5) Place the tube on ice. 
6) Transfer the solution to a 1.5 ml RNase-free non-sticky tube. 
7) Add the following to the tube and incubate at -80 °C for 30 min or overnight 
as desired: 
l 3 M NaOAC, pH 5.2 (2 μl) 
l Glycogen (2 μl) 
l 100% EtOH (60 μl) 
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8) Centrifuge the tube at 14,000 rpm for 25 min at 4 °C in a microcentrifuge. 
9) Carefully pipette off the EtOH without dislodging the RNA pellet. 
10) Without disturbing the pellet, wash the pellet with 300 μl of 70% EtOH. 
11) Centrifuge the pellet and carefully pipette out the 70% EtOH. 
12) Air-dry the pellet for 10 min at room temperature. 
13) Resuspend the RNA in 11.1 μl of RNase-free water. 
4. Synthesize the First Strand cDNA 
1) Assemble the following reaction in a 200 μl thin wall PCR tube: 
l Random Primers (1 μl) 
l mRNA (11.1 μl) 
l The total volume should be 12.1 μl. 
2) Incubate the sample in a PCR thermal cycler at 65 °C for 5 min, and then 
place the tube on ice. 
3) Set the PCR thermal cycler to 25 °C. 
4) Mix the following reagents in the order listed in a separate tube. Multiply each 
volume by the number of samples being prepared. Prepare 10% extra 
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reagent mix if you are preparing multiple samples. 
l 5X First Strand Buffer (4 μl) 
l 100 mM DTT (2 μl) 
l 25 mM dNTP Mix (0.4 μl) 
l RNase Inhibitor (0.5 μl) 
l The total volume should be 6.9 μl. 
5) Add 6.9 μl of mixture to the PCR tube and mix well. 
6) Heat the sample in the preheated PCR thermal cycler at 25 °C for 2 min. 
7) Add 1 μl SuperScript II to the sample and incubate the sample in a thermal 
cycler with following program: 
a. 25 °C for 10 min 
b. 42 °C for 50 min 
c. 70 °C for 15 min 
d. Hold at 4 °C 
8) Place the tube on ice. 
5. Synthesize the Second Strand cDNA 
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1) Preheat a PCR thermal cycler to 16 °C. 
2) Add 62.8 μl of ultra pure water to the first strand cDNA synthesis mix. 
3) Add the following reagents to the mix: 
l GEX Second Strand Buffer (10 μl) 
l 25 mM dNTP Mix (1.2 μl) 
4) Mix well and incubate on ice for 5 min or until well-chilled. 
5) Add the following reagents: 
l RNaseH (1 μl) 
l DNA Pol I (5 μl) 
6) Mix well and incubate at 16 °C in a thermal cycler for 2.5 h. 
7) Follow the instructions in the QIAquick PCR Purification Kit to purify the 
sample and elute in 50 μl of QIAGEN EB buffer. 
8) At this point, the sample is in the form of double-stranded DNA. 
6. Perform End Repair 
1) Preheat one heat block to 20 °C and the other heat block to 37 °C. 
2) Prepare the following reaction mix in a 1.5 ml RNase-free non-sticky tube: 
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l Eluted DNA (50 μl) 
l Water (27.4 μl) 
l 10X End Repair Buffer (10 μl) 
l 25 mM dNTP Mix (1.6 μl) 
l T4 DNA Polymerase (5 μl) 
l Klenow DNA Polymerase (1 μl) 
l T4 PNK (5 μl) 
l The total volume should be 100 μl. 
3) Incubate the sample in a heat block at 20 °C for 30 min. 
4) Follow the instructions in the QIAquick PCR Purification Kit to purify the 
sample and elute in 32 μl of QIAGEN EB buffer. 
7. Adenylate 3' Ends 
1) Prepare the following reaction mix in a 1.5 ml RNase-free non-sticky tube: 
l Eluted DNA (32 μl) 
l A-Tailing Buffer (5 μl) 
l 1 mM dATP (10 μl) 
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l Klenow exo (3' to 5' exo minus) (3 μl) 
l The total volume should be 50 μl. 
2) Incubate the sample in a heat block at 37 °C for 30 min. 
3) Follow the instructions in the MinElute PCR Purification Kit to purify the 
sample and elute in 23 μl of QIAGEN EB buffer 
8. Ligate the Adapters 
1) Prepare the following reaction mix in a 1.5 ml RNase-free non-sticky tube: 
l Eluted DNA (23 μl) 
l 2X Rapid T4 DNA Ligase Buffer (25 μl) 
l PE Adapter Oligo Mix (1 μl) 
l T4 DNA Ligase (1 μl) 
l The total volume should be 50 μl. 
2) Incubate the sample at room temperature for 15 min. 
3) Follow the instructions in the MinElute PCR Purification Kit to purify the 
sample and elute in 10 μl of QIAGEN EB buffer. 
9. Purify the cDNA Templates 
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1) Prepare a 50 ml, 2% agarose gel with distilled water and TAE. Final 
concentration of TAE should be 1X at 50 ml. 
2) Load the samples as follows: 
l 2 μl 100 bp DNA Ladder in the first well 
l 10 μl DNA elute from the ligation step mixed with 2 μl of 6X DNA Loading 
Dye in the second well 
l 2 μl 100 bp DNA Ladder in the third well 
l Using ladders on both sides of a sample help locate the gel area to be 
excised, as the band is not visible. 
3) Run the gel at 120 V for 60 min. 
4) Excise a region of gel with a clean gel excision tip and remove the gel slice 
by centrifuging it into a micro-centrifuge tube. The gel slice should contain 
the material in the 200-500 bp range. 
5) Follow instructions in the Qiaquick Gel Extraction Kit to purify the sample and 
elute in 30 μl of QIAGEN EB buffer. (Be sure to add isopropanol per the 
manufacturer’s instructions.) 
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10. Enrich the Purified cDNA Templates 
1) Prepare the following PCR reaction mix in a 200 μl thin wall PCR tube (Make 
10% extra reagent for multiple samples): 
l 5X Phusion Buffer (10 μl) 
l PCR Primer PE 1.0 (1 μl) 
l PCR Primer PE 2.0 (1 μl) 
l 25 mM dNTP Mix (0.5 μl) 
l Phusion DNA Polymerase (0.5 μl) 
l Water (7 μl) 
l The total volume should be 20 μl. 
2) Add 30 μl of purified ligation mix (from step 5 of the previous section) to the 
200 μl PCR tube. 
3) Amplify using the following PCR process: 
a. 30 s at 98 °C 
b. 15 cycles of: 
10 s at 98 °C 
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30 s at 65 °C 
30 s at 72 °C 
c. 5 min at 72 °C 
d. Hold at 4 °C 
4) Follow the instructions in the QIAquick PCR Purification Kit to purify the 
sample and elute in 30 μl of QIAGEN EB buffer. 
2.5. Whole-genome gene expression analysis 
1. The adapter sequences were removed from the raw sequencing data and the 
individual libraries were converted to the FASTQ format.  
2. Sequence reads were aligned to the mouse genome (mm10) with TopHat2 
(v2.0.9) and the resulting alignment files were reconstructed with Cufflinks 
(v2.1.1) and Scripture (beta2).  
3. For mRNA analyses, the RefSeq database (Build 37.3) was chosen as the 
annotation references. The read counts of each transcript were normalized to the 
length of the individual transcript and to the total mapped fragment counts in 
each sample and expressed as FPKM of mRNAs in each sample.  
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4. The mRNA differential expression analyses were applied for exposed and control 
groups. An adjusted P value <0.05 (Student’s t-test with Benjamini-Hochberg 
FDR adjustment) was used as the cut-off for significantly differentially expressed 
genes. 
5. DEGs were analyzed by enrichment analyses to detect over-represented 
functional terms present in the genomic background.  
6. GO analysis was performed using the GO-seq R package, in which gene length 
bias was corrected. 
2.6. Reverse transcription PCR 
(According to instructions from Invitrogen) 
1. Mix and briefly centrifuge each component before use. 
2. Combine the following in a 0.2 or 0.5 ml tube: 1) RNA 1 μl; 2) 50 µM oligo 1 μl; 3) 
10 mM dNTP mix; 4) DEPC-treated water 7 μl. 
3. Incubate the tube at 65 °C for 5 min, then place on ice for at least 1 min. 
4. Prepare the following cDNA Synthesis Mix, adding each component in the 
indicated order: 1) 10X RT buffer 2 µl; 2) 25 mM MgCl2 4 µl 40 µl; 3) 0.1 M DTT 2 
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µl 20 µl; 4) RNaseOUT™ (40 U/µl) 1 µl; 5) SuperScript® III RT (200 U/µl) 1 µl. 
5. Add 10 μL of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, and 
collect by brief centrifugation. Incubate 50 min at 50 °C. 
6. Terminate the reactions at 85 °C for 5 min. Chill on ice. 
7. Collect the reactions by brief centrifugation. Add 1 μl of RNase H to each tube 
and incubate the tubes for 20 min at 37 °C. 
2.7. qRT-PCR 
1. Total RNAs were isolated and quality controlled using protocols from Illumina, 
Inc. All cDNAs were synthesized using Superscript III (Invitrogen; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). Five over‑ and under-expressed genes were 
selected for qRT-PCR assay. All qRT‑PCR primers are presented in Table 2-1. 
All qPCR reactions were performed on a Roche Lightcycler 480 PCR system 
(Roche Applied Science, Penzberg, Germany) using Toyobo Thunderbird SYBR 
RT‑qPCR Mix (Toyobo Life Science, Osaka, Japan), with three technical repeats. 
2. Set up the experiment and the following PCR program on ABI Prism SDS 7000.  
1) 95 °C 5 min, 1 cycle 
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2) 95 °C 10 s -> 60 °C 20 s, 40 cycles 
3. A real-time PCR reaction mixture is 50 μl. 
1) 25 μl SYBR Green Mix (2x) 
2) 0.5 μl liver cDNA 
3) 2 μl primer pair mix (5 pmol/μl each primer) 
4) 22.5 μl H2O 
4. Relative quantification of target genes was performed using 2-ΔΔCT methods with 
GAPDH as a reference gene. Pearson correlation was used to calculate the 
association between RNA sequence and qRT‑PCR. 
Table2-2 Primers for qRT-PCR 
Gene Primers 
GAPDH F: TGCACCACCAACTGCTTAGC; R: GGCATGGACTGTGGTCATGAG 
Ndufa5 F: GGTGTGCTGAAGAAGACCAC; R: GGTTCCGCTTTAACCATAGCC 
Hsd17b10 F: CGGTAATAACCGGAGGAGCC; R: TGGTCATCACCCGGATACCT 
Ndufa11 F: GTCACACTCAATCCTCCGGG; R: CGCTATGCCAAAGTACACGC 
Cox8a F: CGCCAAGATCCATTCGTTGC; R: TCACGAAGCAGGAGGTAAGC 
Ndufa3 F: CCCCATTGAGCCCCTACTTC; R: CGGGCACTGGGTAGTTGTAG 
EP300 F: CCCCAGATGGGAGGACAAAC; R: ACTGGCTCCAATCTGCTGTC 
Clock F: GGCCACTATGTGAGAACCCC; R: GACAGTCGTCCACGTTCACT 
Postn F: CAACGCAGCGCTATTCTGAC; R: TCGGAAGCCACTTTGTCTCC 
Notch1 F: GAATGGCGGGAAGTGTGAAG; R: CACAGCTGCAGGCATAGTCT 
Klf4 F: GGGAGAAGACACTGCGTCAA; R: GGAAGTCGCTTCATGTGGGA 
Crebbp F: TGAGAACTTGCTGGACGGAC; R: CACTGAGGCTGGCCATGTTA 
UTX F: AGCTTTTGTCGAGCCAAGGA; R: GCATTGGACAAAGTGCAGGG 
 Sirt1 F: GACTCCAAGGCCACGGATAG; R: TGTTCGAGGATCTGTGCCAA 




1) Collect up to 108 (100 M) cells for probe sonication process and re-suspend 
in 10 ml PBS in 15 ml conical tube. 
2) Add 0.28 ml fresh 36.5 % formaldyhyde (FA) in PBS (Final concentration 
1%). Rotate on a rocker for 10 min at room temperature. 
3) Add 1.469 ml 1M Glycine to neutralize FA cross-linking (Final concentration 
0.125 M), rotate on a rocker for 10 min at room temperature. 
4) 500 g, 4 °C, 5 min to pellet samples. 
5) Cold 5 ml PBS wash samples 1-2 times, 500 g, 4 °C, 10 min to pellet 
samples. 
6) Aspirate left media as much as you can, quickly freeze samples in 
Ethonal/Dry ice, and then keep at -80 °C. 
2. Sonication via Diagenode sonicator 
1) Ensure Diagenode Chiller is filled with ddH2O. Turn sonicator on and set 
chiller to 4 °C. Add ice every 5 times after sonication 
2) Thaw cross-linked cells (20 million cells) on ice for 10 min. 
3) Resuspend cells in 6 ml Buffer I (Cytoplasm Lysis Buffer), rotate in the cold 
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room for 10 min. Centrifuge at 1,000 g for 15 min at 4 °C. 
4) Resuspend the nuclei in 10 ml Buffer II (Nuclei Lysis Buffer), rotate in the 
cold room for 10 min. Centrifuge at 1,000 g for 15 min at 4 °C to pellet the 
nuclei. 
5) Add 2 ml Lysis Buffer B with 1 mM PMSF and 1x Proteinase inhibitor 
cocktail. Mix every 3-4 min for better lysis. Lysis the nuclei on ice for 10 min.  
6) Aliquot 0.5 ml of sample into each1.7 ml DENVILLE C2170 tube. Set 
Diagenode Biorupter 200 at “High” power, 30 s on/30 s off, and 20-22 min. 
7) Take out 10 μl shearing sample, add 79 μl TE, 2 μl 5M NaCl (final 100mM), 
4 μl Proteinase K, 5 μl 10%SDS (final 0.5%), incubate for at least 1h at 
65 °C. Take to room temperature and add 2 μl RNaseA (for totally 100 μl 
reaction), incubate at 37 °C for 30min.  
8) Clean samples via phenol/chloroform (PCI) extraction. Add equal volume of 
PCI (100 μl), vortex vigorously and centrifuge at max speed for 10 min (RT).  
9) Aspirate 20 μl of the upper layer, mix with 4 μl loading dye, run a 1.5-2 % 
agarose gel at 80-100 V for 30-40 min. (Ideally between 100-500bp) 
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3. Chromatin IP 
1) After Sonication, 13,000-14,000 rpm, 10 min, 4 °C. 
2) Collect supernatant, avoiding bottom dark cell debris. Estimate how much 
supernatant you collect, For example, ~1.8 ml. Initial 6 M cells can be divided 
for up to 10 individual samples for different histone markers (1-0.5 M cells for 
each library). Take 150-180 μl for experiment. 
3) Adding 9 volume ChIP dilution Buffer (0.1x) to reduce SDS lower than 0.1%. 
SDS is bad for protein binding and ChIP.  
4) Adding again to 1x proteinase inhibitor cocktail (~18 μl). 
5) Take out 10% of solution as control 
6) Add 5% glycerol for storage in -20 °C.  
7) Adding histone antibody and IP overnight 12-16 h, 4 °C. Titrate antibody 
especially for low cell number ChIP (too much antibody even can pull-down 
bacteria DNA). It is better to make master-mix of your antibody in ChIP 
dilution Buffer (0.1x) and add 10 μl-diluted antibody. 
8) Adding 40 μl Protein A or G beads for 2 ml volume, 4-5 h. 
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9) Low salt wash 1x, 1 ml, 2 min, 4 °C. 
10) High salt wash 1x, 1 ml, 2 min, 4 °C. 
11) LiCl wash 1x, 1 ml, 2-3 min, 4 °C. 
12) TE Buffer wash 2x, 1 ml, 2-3 min, RT 
13) Resuspend the beads in 100 μl TE and transfer to a new 1.5 ml tube. 
14) Adding master mixed 55 μl proteinase K solution (50 μl 10mMTris-CL, PH8.0, 
600 mM sodium chloride, +2.5 μl 10% SDS+2.5 μl 20 mg/ml proteinase K). 
55-65 °C, overnight. 
4. Chromatin DNA Recovery 
1) Let samples cool down to room temperature. 
2) Capture beads on magnetic rack at room temp. 
3) Remove 150 μl of sup and add into clean nonstick DNAse-free 1.5 ml tube  
4) Add RNA enzyme 3 μl (50 μl system for 1 μl RNAse), incubate at 37 °C for 
30 min. 
5) Add 150 μl (equal to the system) Phenol: Chloroform: Isoamy Alcohol 
25:24:1 into the tube (from the bottom layer). 
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6) Pipet several times to mix. 
7) Centrifuge at 12,000 rpm for 15 min. 
8) Move the upper layer into another tube. 
9) Add 500 μl 100% ethanol; 3.5 μl 5 mg/ml Linear Acrylamide; 20 μl 3M 
NaOAc, pH 5.3 to the supernatant to precipitate DNA. 
10) Gently mix by turn the tube up and down for several times. 
11) Centrifuge at 12,000 rpm for 15 min. 
12) Discard the supernatant carefully, and then add 750 μl 70% ethanol. 
13) Centrifuge at 8,000 rpm for 5 min. 
14) Discard the supernatant. Let the tube air dry at Room Temperature for 5 min. 
15) Add pure water to dissolve DNA. 
5. End Repair 
1) Add 40 μl of End Repair Mix to each well. Mix by pipetting 10 times. 
2) Incubate in a PCR machine for 30 min at 30 °C. 
3) Ampure clean up: Dilute Ampure beads to 0.85X; Add 160 μl bead mixture to 
each well containing 100 μl of End repaired reaction. 
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4) Clean up with Ampure beads (1.8X): Resuspend the dried pellet with 19.5 μl 
Resuspension Buffer.  
5) Transfer 15 μl of the clear supernatant to new PCR strips. 
6. Adenylation 3¢ Ends 
1) Add 12.5 μl of A-Tailing Mix to each well. Mix by pipetting 10 times. 
2) Incubate in a PCR machine with program “ATAIL70” (37 °C for 30 min; 70 °C 
for 5 min; hold at 4 °C). Proceed immediately to Ligate Adaptors 
7. Ligate Adaptors 
1) Add 4.5 μl of Resuspension buffer to each well. 
2) Remove the Ligation Mix from -20 °C freezer. Add 2.5 μl to each well.  
3) Return the Ligation Mix to -20 °C freezer IMMEDIATELY after use. 
4) Add 0.5 μl of Adapter Index. Mix by pipetting 10 times. 
5) Incubate at 30 °C for 10 min. 
6) Add 5 μl of Stop Ligation Buffer to each well. Mix by pipetting 10 times. 
8. Clean up 
1) 42.5 μl (1:1) Ampure purification twice. First resuspension: 52.5 μl 
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resuspension buffer; Second resuspension 22.5 μl resuspension buffer.  
2) Gel-free method: Transfer 20 μl of the clear supernatant to new PCR strips;  
3) E-gel purification: 250~550 bp 
4) MinElute gel purification: wash with 25 μl EB 
5) Transfer 20 μl to PCR tubes 
9. PCR 
1) Thaw the PCR Master Mix and PCR Primer Cocktail at RT. Once thawed, 
keep the tubes on ice. 
2) PCR layout 
DNA-Adaptor: 20 μl 
PCR Primer Cocktail: 5 μl  
PCR Master Mix: 25 μl 
3) Program: 98 °C 30 s; 98 °C 10 s, 60 °C 30 s, 72 °C 30 s 10X; 72 °C 5 min; 
4 °C forever (Kong et al. 2000).  
10. Clean up 
1) Add 50 μl of Ampure XP beads to 32.5 μl Resuspension Buffer. 
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2) (Optional): Gel purification of libraries 80 V 90 min. 
3) Cut only the lower band 250~350 bp 
4) The upper band usually gives you a mixture of different sizes.  
5) Validate library by Bioanalyzer 
2.9.  Identification of binding regions and peaks 
1. For ChIP-seq of H3K4me1 and H3K27ac, reads were mapped to the mm10 
genome using Bowtie aligner allowing up to two mismatches. Only the uniquely 
mapping reads were used for further analysis.  
2. Macs2 call peak program was used to call the peaks and the macs2 bdgdiff was 
used to identify the difference between MEF and Dot1L. 
2.10. ChIP-qPCR validation 
Five genes’ promoters were selected for qRT-PCR assay and presented in Table 2-3. 
All qPCR reactions were performed on a Roche Light-cycler 480 PCR system using 
Toyobo Thunderbird SYBR RT‑qPCR Mix, with three technical repeats. The 
amplification procedure was as follows: 95 ˚C for 5 min, followed by 40 cycles of 95 
˚C for 10 sec and 60 ˚C for 20 sec. The cycle threshold (Ct) of samples was used for 
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calculation. Each value was normalized to the percentage of Input DNA by using 
IP/INPUT= 2 CtINPUTDNA-CtIPDNA . 
Table2- 3 Primers for ChIP-PCR 
Gene Location 
(5¢-3¢) 
Sequence Size (bp) 

























2.11. Statistical analysis 
Results were presented in Means ± standard error of the mean (SEM). Student's 
t-test was used to examine difference between two groups and ANOVA was used for 




3.1. Identification of a low dose exposure condition 
Toward a low dose exposure condition for epigenetic insights of arsenite 
exposure, we set up exposure experiments and used Nrf2 expression as an indicator 
to characterize. Based on previous reports, we started our exposure experiments with 
two time points (6 and 24 h) and four concentrations (0, 2, 5, and 10 μM). Without 
arsenite exposure, there was limited amount of Nrf2 expressed in both MEF and 
Dot1L-/- cells (Figure 3-1). After 6 h treatment, the amount of Nrf2 showed 
dose-effect relationships with the concentrations of sodium arsenite in both cell lines 
(Figure 3-2). In addition, there was a significant difference between 2 μM and 5 μM 
groups. Results after 24 h exposure (Figure 3-3) were similar to 6 h treatment. 
However, compared with 6 h groups, which showed same results in both cells, 24 h 
groups (Figure 3-4) showed different pattern of Nrf2 expression, which might be 
caused by Dot1L lacking. Collectively, we considered 5 μM and 24 h were 
appropriate for our mechanistic exploration and chose this exposure condition for 
further experimental characterizations. 
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Figure3-1 Expression of Nrf2 after 6 h exposure of arsenite at different concentrations 
 





Figure3-3 Expression of Nrf2 after 24 h exposure of arsenite at different 
concentrations 
 




3.2.  RNA-seq analyses 
To identify an intermediate factor bridging (external) environmental exposure and 
(internal) cellular pathway changes, we focused on transcriptional changes. To our 
goal, we purified mRNAs from exposed cells and followed our established protocols 
for RNA-seq library construction (Li et al., 2015). Sequenced reads were aligned to 
the mouse genome, and expression changes were analyzed. Arsenite treatment 
increased 518 genes in MEF and 696 genes in Dot1L-/-. And the overlapping genes 
were 339 in two cell lines (Figure3-5). Arsenite treatment also down-regulated genes, 
with 158 genes in MEF and 413 genes in Dot1L-/- MEF cells and the overlapping 
genes were 101 (Figure 3-6). Top 10 up-regulated and down-regulated GO terms in 
both cells were shown in Figures 3-7, 3-8, 3-9 and 3-10. To further validate our 
RNA-seq results, we selected 10 genes (Up-regulated genes were chosen among 
genes that played roles in response to oxidative stress and down-regulated genes 
were chosen among gene that played roles in epigenetics or tumor initiation) for 
qRT-PCR analyses in both cell lines and confirmed their expression changes 
(Figures 3-11 and 3-12). R squares from Pearson correlation analyses were 0.85 for 
MEF and 0.90 for Dot1L-/-, suggesting the results from our RNA-seq analyses were 
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reliable (Figure 3-13 and 3-14). 
 
Figure3-5 Overlapping of up-regulated genes in MEF and Dot1L after 24 h arsenite 
exposure 
 





Figure3- 7 Top 10 up-regulated GO terms in MEF after 24 h arsenite exposure 
 




Figure3-9 Top 10 up-regulated GO terms in Dot1L-/- after 24 h arsenite exposure 
 




Figure3-11 Validation of mRNA-seq results through qRT-PCR in MEF cell 
 
Figure3-12 Validation of mRNA-seq results through qRT-PCR in Dot1L-/- 
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Figure3-13 Correlation between mRNA-seq and qRT-PCR in MEF cell  
 
Figure3-14 Correlation between mRNA-seq and qRT-PCR in Dot1L-/- cell   
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3.3.  Arsenite exposure inhibited histone acetyltransferase p300 
Among these 101 overlapping genes that were inhibited by arsenite treatment in 
two cell lines, we noticed an intriguing candidate, EP300 (Log2 fold, -3.5 in MEF cell 
and -4.6 in Dot1L-/-) (Figures 3-11 and 3-12). EP300 encodes histone 
acetyltransferase p300 (also known as E1A-associated protein p300), essential for 
regulating cell growth and differentiation and preventing the growth of tumors. For the 
latter, many have reported the role of p300 as a tumor suppressor (Iyer et al., 2004). 
We first did qRT-PCR (Figures 3-11 and 3-12) and validated these observed 
changes from RNA-seq analyses. Because reduced RNA level may not reflect the 
actual protein level and the protein executes enzymatic activity, we next did Western 
blot to reveal the exact p300 protein level within cells. Western blot from three 
biological replicates demonstrated that arsenite exposure indeed reduced p300 
protein level and showed dose-effect relationship with arsenite concentrations 
(Figures 3-15 and 3-16). In combination with mRNA-seq and qRT-PCR data, we 
conclude that arsenite exposure reduces the expression of EP300 initially at the 




Figure3-15 Expression levels of p300 and signal level of H3K27ac and H3K4me1 in 
MEF and Dot1L-/- after 24 h exposure of arsenite with different concentrations 
 
Figure3-16 Quantitative results of p300 expression after 24 h exposure of arsenite at 
different concentrations 
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3.4. Decreased H3K27ac after arsenite exposure 
Next, we determined the consequence after the abolishment of p300 due to 
arsenite exposure. As a HAT, p300 is expected to acetylate nucleosomal tails. 
Though p300 seems to acetylate many residues of histone H3 or H4 especially from 
in vitro assays, there are also reports suggesting H3K27ac as p300-sepcific mark (Li 
et al., 2011; Tang et al., 2013). Therefore, we examined the changes of H3K27ac 
after arsenite exposure. With the increasing concentration of arsenite, our data 
demonstrated that the levels of H3K27ac decreased accordingly (Figures 3-15 and 
3-17) from three replicates. These data demonstrated that arsenite exposure caused 
decreases of histone H3K27ac, as a consequence of diminished p300.  
 
Figure3-17 Quantitative results of H3K27ac signal after 24 h exposure of arsenite at 
different concentrations 
 63 
3.5. Decreased H3K4me1 after arsenite exposure 
In epigenetic community, both H3K27ac and H3K4me1 are two well-known 
markers for enhancers. With H3K27ac down, we asked the extent to which H3K4me1 
changed accordingly. To our aim, we checked the signals of H3K4me1 in the same 
samples. Intriguingly, our Western blot results from three replicates reveal the 
concomitant decreases of H3K4me1 (Fig. 3-15 and 3-18). These data collectively 
suggested that arsenite exposure involved underappreciated crosstalk between two 
enhancer markers, H3K27ac and H3K4me1. 
 
Figure3-18 Quantitative results of H3K4me1 signal after 24 h exposure of arsenite at 
different concentrations 
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3.6. Vulnerable genomic loci with reduced H3K27ac and H3K4me1 
Data of our Western blotting assays revealed changes of histone acetylation at 
the global level. To identify the vulnerable genomic loci with altered chromatin after 
arsenite exposure, we did ChIP-seq analyses using a previously characterized 
anti-H3K27ac (Wang et al., 2008; Wang et al., 2009). Following our established 
pipeline, we analyzed H3K27ac ChIP-seq signals genome wide in MEF cell. As 
expected, arsenite exposed sample has much less H3K27ac peaks compared to 
control samples. There are 4,772 peaks specific to exposed sample, whereas 18,302 
peaks specific to control sample. Two samples shared 21,548 peaks (Figure 3-19). 
These data are consistent with our Western blotting results (Figure 3-15). 
Furthermore, we also analyzed H3K4me1 ChIP-seq signals genome wide in MEF cell. 
Arsenite exposed sample has much less H3K4me1 peaks compared to control 
samples. There are 674 peaks specific to exposed sample, whereas 7,822 peaks 
specific to control sample. Two samples shared 18,264 peaks (Figure 3-20).  
In Dot1L-/- cell, both antibodies showed similar results. Arsenite exposed sample 
has much less H3K27ac peaks compared to control samples. There are 7,822 peaks 
specific to exposed sample, whereas 14,123 peaks specific to control sample. Two 
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samples shared 15,843 peaks (Figure 3-21). In H3K4me1 ChIP-seq signals genome 
wide, there are 6,742 peaks specific to exposed sample, whereas 29,729 peaks 
specific to control sample. Two samples shared 11,210 peaks (Figure 3-22). 
 








Figure3-21 Peaks between Dot1L-/- cell and arsenite treated Dot1L-/- cell using 
anti-H3K27ac 
 
Figure3-22 Peaks between Dot1L-/- cell and arsenite treated Dot1L-/- cell using 
anti-H3K4me1 
3.7. Decreased H3K27ac and H3K4me1 inhibited gene expression 
Having established that arsenite exposure reduced H3K27ac and H3K4me1, we 
next determined the reductions on transcription of selected genes. Snapshots of 
ChIP-seq and mRNA-seq results were presented for genes, including EP300 (Figure 
3-23), Klf4 (Figure 3-24), Notch2 (Figure 3-25), and Igf2r (Figure 3-26). These data 
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demonstrated that reduction of H3K27ac and H3K4me1 repressed the transcripts of 
these genes. Notice the different scales used for presenting RNA-seq data.  
 
Figure3-23 Snapshots of ChIP-seq and mRNA-seq results of EP300 
 
Figure3-24 Snapshots of ChIP-seq and mRNA-seq results of Klf4 
 
Figure3-25 Snapshots of ChIP-seq and mRNA-seq results of Notch2 
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Figure3- 26 Snapshots of ChIP-seq and mRNA-seq results of Igf2r 
To provide independent confirmation of H3K27ac at these loci and provide 
additional information of H3K4me1, we did ChIP-qPCR analyses. Results from 
Figures 3-27 and 3-28 showed the lower enrichment of five gene promoters after 
arsenic exposure in MEF cell, which were in accordance with ChIP-seq results. Klf4, 
a tumor suppressor gene, showed de-acetylation of H3K27ac and down-regulation 
(Log2 fold, -5.0), which was validated through ChIP-qPCR after arsenite exposure. 
Accompany to the decreases of H3K27ac at these loci, our ChIP-qPCR 
demonstrated the decreases of H3K4me1. These data convinced us that arsenite 
exposure inhibited p300 protein level within cells, thereby impacting histone markers 
for enhancers and transcription start sites for gene transcription.  
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Figure3- 27 ChIP-PCR results of five genes using anti-H3K27ac in MEF cell 
 




Considering the expensive nature of deep sequencing and our focus of 
mechanistic insights to initiate the understanding of epigenomic mechanisms during 
arsenic exposure, we set out experiments for identification of one low dose condition 
for future acute exposure. One more reasonable assumption is that exposure at high 
doses and low doses highly likely shares similar epigenetic mechanism. To our goal, 
we choose 0, 2, 5, and 10 μM sodium arsenite based on published papers (Chervona 
et al. 2012a; Eckstein et al. 2017; Shi et al. 2004; Wang et al. 2013) for treatment. 
We chose to use MEF cells for a few reasons: First, MEF cell line is a common 
model used in toxicology. Second, though still very preliminary, H3K79 methylation 
may be associated with arsenic exposure (Howe et al. 2017). Meanwhile, we have 
Dot1L knockout MEF cells with depleted histone mark H3K79 dimethylataion 
(H3K79me2). Therefore, treatments to both MEF and Dot1L-/- help to determine the 
crosstalk between arsenic exposure and histone H3K79me2 marks in cells. Third, 
treatments of two independent cell lines would serve as replicates for us.  
Currently, it is still not conclusive about inorganic arsenic exposure changing 
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histone acetylations for altering gene expression. For example, inorganic arsenic 
exposure showed H3K27ac and H3K18ac in negative association in females, but 
positive association in males (Chervona et al. 2012b). Sodium arsenite exposure 
increased H3K9ac after 24 h exposure in HepG2 cells (Ramirez et al. 2008), which is 
in dramatic contrast to the decrease of H3K9ac in arsenic exposed mice (Cronican et 
al. 2013a; Pournara et al. 2016). Previous investigations also reported that the 
chronic arsenic exposure decreased H4K16ac in human UROtsa cells (Jo et al. 
2009a), via affecting one of the HATs, MYST1 (also known as MOF). MOF forms two 
distinct multiprotein complexes (MSL and NSL) that both acetylate H4K16ac. Herein, 
through three biological replicates, we demonstrated that acute arsenic exposure 
decreased p300 in both mRNA and protein levels (Fig. 2C, 2D, 3A). Consequently, 
p300-specific H3K27ac was reduced as demonstrated by both ChIP-seq and 
ChIP-qPCR analyses in our exposed mouse MEF cells. In our system, RNA-seq data 
did not show the altered expression of MYST1, different from the case in human 
UROtsa cells. To summarize, three independent investigations including ours 
showed the decreases of histone acetylations (H3K9ac, H3K27ac, or H4K16ac) 
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(Cronican et al. 2013a; Jo et al. 2009a), whereas one report showed a contradictory 
increase of H3K9ac (Ramirez et al. 2008).  
Taken together, it remains to be finalized the changes of histone acetylations and 
affected HAT(s) responsible for the changed histone acetylation upon arsenic 
exposure. From our observation, all three doses showed similar inhibition of p300 
(Figure 3A), maybe ruling out of different doses for different observations (Ramirez et 
al. 2008). We also noticed the different cell types/lines used or differences in model 
system used (animal or cell line). Whether these differences explain the controversies 
of increased or decreased histone acetylation requests further investigation. Lastly, 
our convincing data suggest that the loss of p300 (and resulting H3K27ac) is related 
to inorganic arsenic related diseases. Therefore, it may open a new avenue for 
alleviating the consequence of H3K27ac, for example, via boosting CBP enzymatic 
activity for at least partially compensating p300 functions (Iyer et al. 2004; Kasper et 
al. 2006). 
Both EP300 and its regulated gene Kif4 (silenced after arsenic exposure; Figure 
2C) are tumor suppressors(Iyer et al. 2004). For example, EP300 works as a tumor 
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suppressor in hematological tumors (Kung et al. 2000; Oike et al. 1999). 
Down-expression of p53 and p300 were also found in azoxymethane treated mice, 
which is a colon-specific carcinogen(Aizu et al. 2003). The role of Klf4 as a tumor 
suppressor has been validated in colorectal cancer (Zhao et al. 2004), non-Hodgkin 
lymphoma (Guan et al. 2010), classic Hodgkin lymphoma (Guan et al. 2010), and 
pancreatic ductal carcinoma (Zammarchi et al. 2011). According to our results, it is 
reasonable to speculate that arsenite induced down-regulation of p300, and following 
decreased H3K27ac in Klf4. This change led to down expression of Klf4, which 
promoted the initiation of tumors. Other researchers also reported similar result 
(Evans et al. 2007). 
NQO1 works as an enzyme to catalyze the two-electron detoxification of quinone 
substances. However, several researches reported genetic polymorphisms of Nqo1 
as a risk factor of lung, breast, bladder and prostate cancer (Kiyohara et al. 2002; 
Kiyohara et al. 2005; Lin et al. 2003; Wang et al. 2017; Yang et al. 2014). Besides, 
among non-small cell lung cancer patients, increasing expression Nqo1 protein 
expression predicts poor outcome(Li et al. 2015). Arsenic induced NQO1 expression 
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by recruiting Nrf2·Maf to the ARE Enhancer(He et al. 2006). Both mRNA and protein 
levels of NQO1 increased dramatically after inorganic arsenic exposure in Chang 
human hepatocytes(Liu et al. 2013). Our data also showed the up-regulation of 
NQO1 in arsenite treated MEF cell. 
In epidemiological researches, mutation of Igf2r had been found in breast, liver 
and lung cancers(Jang et al. 2008; Kong et al. 2000; Oka et al. 2002). The role of 
Igf2r as a tumor suppressor gene was validated in 1999 since the inhibition of Igf2r 
transcription led to increasing cell growth in JEC-3 cells(O'Gorman et al. 1999). 
Besides, loss of heterozygosity has been viewed as an early event in liver and breast 
carcinogenesis (Oates et al. 1998; Yamada et al. 1997). In Dot1L mRNA-seq results, 
we found the lower expression of Igf2r, which might be a mechanism of 
arsenic-related tumors. 
In conclusion, for the first time, we reported that sodium arsenite inhibit EP300 in 
both mRNA and protein levels, which led to the decreased H3K27ac signal. Further 
experiments should be finished to confirm whether this mechanism can be observe in 
the long term exposure of arsenite or in the mouse model. If this mechanism exists in 
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